Alzheimer’s (AD) and Parkinson’s (PD) are the two most common neurodegenerative disorders that affect millions of people worldwide, but their therapeutic opportunities are limited. Resveratrol, a hydrophobic stilbene flavonoid from various sources, including red wine, peanuts, and grapes, has been reported for its effectiveness in multiple diseases, including cancer, cardiovascular disease, and neurological disorders. The mechanism and effect of Resveratrol in AD and PD are also elaborated in detail. Resveratrol can cross the blood–brain barrier (BBB) to exert its pharmacological action. However, the therapeutic dose for its action was not achieved due to its extensive metabolite formation with glucuronide and sulfate. Hence, the discussion on the same has also been reviewed in this article. The development of promising approaches to improve the resveratrol to traverse across the BBB may help the challenges associated with brain delivery. Various studies have reported that nanotechnology-based resveratrol delivery could enhance the multiple outcomes in neurological disorders. Furthermore, preclinical and clinical findings are required to prove the effectiveness of managing AD and PD.
Key words: KEYWORDS: Alzheimers disease, Parkinson disease, Resveratrol, Nanotechnology, Brain delivery
|
